Format
Sort by

Send to

Choose Destination

Search results

Items: 16

1.

Prevalence of and factors associated with depression among people living with HIV in France.

Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group..

HIV Med. 2016 Sep 14. doi: 10.1111/hiv.12438. [Epub ahead of print]

PMID:
27625202
2.

Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.

Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group..

J Int AIDS Soc. 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095.

3.

Sub-Saharan African migrants living with HIV acquired after migration, France, ANRS PARCOURS study, 2012 to 2013.

Desgrées-du-Loû A, Pannetier J, Ravalihasy A, Gosselin A, Supervie V, Panjo H, Bajos N, Lert F, Lydié N, Dray-Spira R; Parcours Study Group5..

Euro Surveill. 2015;20(46). doi: 10.2807/1560-7917.ES.2015.20.46.30065. Erratum in: Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30069.

4.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group..

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
5.

Is hardship during migration a determinant of HIV infection? Results from the ANRS PARCOURS study of sub-Saharan African migrants in France.

Desgrees-du-Lou A, Pannetier J, Ravalihasy A, Le Guen M, Gosselin A, Panjo H, Bajos N, Lydie N, Lert F, Dray-Spira R; PARCOURS Study Group..

AIDS. 2016 Feb 20;30(4):645-56. doi: 10.1097/QAD.0000000000000957.

6.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3.

7.

Has the employment status of people living with HIV changed since the early 2000s?

Annequin M, Lert F, Spire B, Dray-Spira R; VESPA2 Study Group..

AIDS. 2015 Jul 31;29(12):1537-47. doi: 10.1097/QAD.0000000000000722.

PMID:
26244393
8.

Women living with HIV still lack highly effective contraception: results from the ANRS VESPA2 study, France, 2011.

Maraux B, Hamelin C, Bajos N, Dray-Spira R, Spire B, Lert F; Vespa2 study group..

Contraception. 2015 Aug;92(2):160-9. doi: 10.1016/j.contraception.2015.04.010.

PMID:
25940932
9.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group..

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914.

PMID:
25723557
10.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167.

11.

Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).

Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group..

AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553.

PMID:
24731158
12.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts..

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

13.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration..

AIDS. 2012 Aug 24;26(13):1691-705.

14.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration..

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203.

15.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration., Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

16.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration., Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

Items per page

Supplemental Content

Loading ...
Support Center